中华放射医学与防护杂志
中華放射醫學與防護雜誌
중화방사의학여방호잡지
Chinese Journal of Radiological Medicine and Protection
2013年
3期
290-293
,共4页
张天%苑惠敏%毛凯%任晔%任既晨%刘德志%王斌%王宗烨
張天%苑惠敏%毛凱%任曄%任既晨%劉德誌%王斌%王宗燁
장천%원혜민%모개%임엽%임기신%류덕지%왕빈%왕종엽
肿瘤标志物%癌胚抗原%CA125%CYFAR21-1%鳞状细胞癌相关抗原%放疗%非小细胞肺癌
腫瘤標誌物%癌胚抗原%CA125%CYFAR21-1%鱗狀細胞癌相關抗原%放療%非小細胞肺癌
종류표지물%암배항원%CA125%CYFAR21-1%린상세포암상관항원%방료%비소세포폐암
Tumor marker%CEA%CA125%CYFAR21-1%SCC%Radiotherapy%Nonsmall cell lung cancer
目的 回顾性研究晚期非小细胞肺癌患者放疗前后血清CEA、CYFAR21-1、SCC、CA125的水平变化,探讨血清肿瘤标志物的改变及与放疗近期疗效的关系.方法 常规检查205例经确诊的晚期非小细胞肺癌患者放疗前、后血清CEA、CYFAR21-1、SCC、CA125等肿瘤标志物的水平(应用电化学发光法),同时评估放疗的近期疗效,分析肿瘤标志物的变化及与近期疗效的关系.结果 205例患者放疗后近期有效113例,总有效率为55.1％.此113例患者放疗后血清CEA、CYFAR21-1、SCC、CA125水平均较放疗前发生了明显下降(t=3.224,2.896,3.137,3.219,P＜0.05),其中Ⅲ期及Ⅳ期患者血清肿瘤标志物CEA、CYFAR21-1、SCC、CA125放疗后与放疗前比较,差异均有统计学意义(Ⅲ期:t =2.484,2.445,2.148,2.109,P＜0.05；Ⅳ期:t=2.072,2.857,2.277,2.436,P＜0.05)；而放疗后近期非有效的92例患者中,放疗后血清肿瘤标志物较放疗前明显上升(t=2.224,2.005,2.261,2.545,P＜0.05).放疗后肿瘤标志物降低组的近期疗效明显好于肿瘤标志物升高组,差异有统计学意义(x2=80.001,P＜0.01)结论 血清肿瘤标志物CEA、CYFAR21-1、SCC、CA125水平或可用于晚期非小细胞肺癌患者放疗后的近期疗效评估.
目的 迴顧性研究晚期非小細胞肺癌患者放療前後血清CEA、CYFAR21-1、SCC、CA125的水平變化,探討血清腫瘤標誌物的改變及與放療近期療效的關繫.方法 常規檢查205例經確診的晚期非小細胞肺癌患者放療前、後血清CEA、CYFAR21-1、SCC、CA125等腫瘤標誌物的水平(應用電化學髮光法),同時評估放療的近期療效,分析腫瘤標誌物的變化及與近期療效的關繫.結果 205例患者放療後近期有效113例,總有效率為55.1％.此113例患者放療後血清CEA、CYFAR21-1、SCC、CA125水平均較放療前髮生瞭明顯下降(t=3.224,2.896,3.137,3.219,P＜0.05),其中Ⅲ期及Ⅳ期患者血清腫瘤標誌物CEA、CYFAR21-1、SCC、CA125放療後與放療前比較,差異均有統計學意義(Ⅲ期:t =2.484,2.445,2.148,2.109,P＜0.05；Ⅳ期:t=2.072,2.857,2.277,2.436,P＜0.05)；而放療後近期非有效的92例患者中,放療後血清腫瘤標誌物較放療前明顯上升(t=2.224,2.005,2.261,2.545,P＜0.05).放療後腫瘤標誌物降低組的近期療效明顯好于腫瘤標誌物升高組,差異有統計學意義(x2=80.001,P＜0.01)結論 血清腫瘤標誌物CEA、CYFAR21-1、SCC、CA125水平或可用于晚期非小細胞肺癌患者放療後的近期療效評估.
목적 회고성연구만기비소세포폐암환자방료전후혈청CEA、CYFAR21-1、SCC、CA125적수평변화,탐토혈청종류표지물적개변급여방료근기료효적관계.방법 상규검사205례경학진적만기비소세포폐암환자방료전、후혈청CEA、CYFAR21-1、SCC、CA125등종류표지물적수평(응용전화학발광법),동시평고방료적근기료효,분석종류표지물적변화급여근기료효적관계.결과 205례환자방료후근기유효113례,총유효솔위55.1％.차113례환자방료후혈청CEA、CYFAR21-1、SCC、CA125수평균교방료전발생료명현하강(t=3.224,2.896,3.137,3.219,P＜0.05),기중Ⅲ기급Ⅳ기환자혈청종류표지물CEA、CYFAR21-1、SCC、CA125방료후여방료전비교,차이균유통계학의의(Ⅲ기:t =2.484,2.445,2.148,2.109,P＜0.05；Ⅳ기:t=2.072,2.857,2.277,2.436,P＜0.05)；이방료후근기비유효적92례환자중,방료후혈청종류표지물교방료전명현상승(t=2.224,2.005,2.261,2.545,P＜0.05).방료후종류표지물강저조적근기료효명현호우종류표지물승고조,차이유통계학의의(x2=80.001,P＜0.01)결론 혈청종류표지물CEA、CYFAR21-1、SCC、CA125수평혹가용우만기비소세포폐암환자방료후적근기료효평고.
Objective To investigate the change of the serum levels of CEA,CYFAR21-1,SCC,CA125 in advanced non-small cell lung cancer.patients before and after radiotherapy retrospectively and to explore the relationship between the change of serum tumor markers and the short-term efficacy of radiotherapy.Methods The serum levels of CEA,CYFAR21-1,SCC,CA125 in 205 cases with advanced non-small cell lung cancer were detected (by electro-chemiluminescence immunoassay method)before and after radiotherapy,and the short-term efficacy of radiotherapy was assessed (RECIST 1.1 edition) at the same time.The changes in tumor markers and the short-term efficacy were analyzed.Results Totally 113 patients achieved response of short-term efficacy after radiotherapy,and the effective rate of the short-term efficacy was 55.1％.Among these 113 patients,the serum levels of tumor markers decreased significantly after radiotherapy(t =3.224,2.896,3.137,3.219,P ＜ 0.05).The serum levels of tumor markers in patients with stage Ⅲ and Ⅳ decreased after radiotherapy (t =2.484,2.445,2.148,2.109,P ＜ 0.05 ;t =2.072,2.857,2.277,2.436,P ＜ 0.05).Among 92 patients who did not achieve response of short-term efficacy,the serum level of tumor markers increased significantly after radiotherapy(t=2.224,2.005,2.261,2.545,P ＜ 0.05).For the patient who achieved response of radiotherapy with tumor markers decreased,the short-term efficacy was significantly better than the group of which tumor maker increased (x2 =80.001,P ＜ 0.01).Conclusions The serum levels of CEA,CYFAR21-1,SCC,CA125 can be used for assessment of short-term efficacy after radiotherapy in advanced non-small cell lung cancer patients.
